Skip to Content
Merck

Skip To

S7076

SB 202190 monohydrochloride hydrate

≥98% (HPLC), solid, p38 MAP kinase inhibitor

Synonym(s):

4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole monohydrochloride hydrate, 4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol monohydrochloride hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C20H14FN3O · HCl · xH2O
CAS Number:
Molecular Weight:
367.80 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Storage condition:
desiccated
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

SB 202190 monohydrochloride hydrate, ≥98% (HPLC)

Quality Segment

assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to beige

solubility

DMSO: ≥12 mg/mL

originator

GlaxoSmithKline

storage temp.

2-8°C

SMILES string

O.Cl.Oc1ccc(cc1)-c2nc(-c3ccc(F)cc3)c([nH]2)-c4ccncc4

InChI

1S/C20H14FN3O.ClH.H2O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15;;/h1-12,25H,(H,23,24);1H;1H2

InChI key

CZZOICWZVYZUNP-UHFFFAOYSA-N

Application

SB 202190 monohydrochloride hydrate has been used as a component of human prostate culture medium and organoid culture medium It has also been used as p38 mitogen activated protein kinase (MAPK) inhibitor in colon cancer cells.[1]
SB 202190 may be used to inhibit p38-mediated cell signaling.

Biochem/physiol Actions

SB 202190 monohydrochloride hydrate mediates the phosphorylation of serine in the mutant p53 protein and modulates cell adhesion and prevents cell proliferation in breast cancer cell lines.
SB 202190 binds within the ATP pocket of p38 kinase and inhibits the p38α and β isoforms.
SB 202190 is a highly selective, potent, and cell-permeable inhibitor of p38 MAP kinase.

Features and Benefits

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
S7067S4317S9070
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

solid

form

powder

form

powder

form

solid

Quality Level

100

Quality Level

100

Quality Level

300

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

-

storage condition

desiccated

storage condition

-

storage condition

-

storage condition

-

solubility

DMSO: ≥12 mg/mL

solubility

DMSO: 10 mg/mL, clear

solubility

DMSO: soluble 10 mg/mL, H2O: insoluble

solubility

H2O: 22 mg/mL


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Questions

Reviews

No rating value

Active Filters